Individualized intensified antiplatelet therapy based on platelet reactivity testing reduces the incidence of cardiovascular events in patients undergoing percutaneous coronary intervention

References (5)

1. Jeong YH, Ahn JH, Shin ES. Impact of high on-treatment platelet reactivity on long-term clinical events in AMI patients: a fact or mirage? Anatol J Cardiol 2016 Nov 16. Epub ahead of print
2. Zhou Y, Wang Y, Wu Y, Huang C, Yan H, Zhu W, et al. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a metaanalysis of randomized controlled trials. BMC Cardiovasc Disord 2017; 17: 157
3. Bagai A, Peterson ED, McCoy LA, Effron MB, Zettler ME, Stone GW, et al. Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. Am Heart J 2017; 187: 19-28
4. Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, et al. Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014; 63: 1061-70
5. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541619.